Sept 26 (Reuters) - The U.S. Food and Drug
Administration on Thursday alerted patients and healthcare
professionals about the withdrawal of Pfizer's ( PFE ) sickle
cell disease treatment Oxbryta.
Pfizer ( PFE ) said late on Wednesday it was pulling the drug from
all markets due to risk of a painful complication and death.
The FDA said it was conducting a safety review of
postmarketing clinical data for the drug, and will also review
real world registry studies.